EXHIBIT 99.2

             CannaPharmaRx, Inc. Announces New Financial Controller
                         to be based in NJ Headquarters


December 4, 2014:  CannaPharmaRx,  Inc.,  (OTCQB:  GDHC),  the New  Jersey-based
pharmaceutical  research and discovery  company,  today  announced the hiring of
Thomas J. Della-Franco III as Financial  Controller.  Mr. Della-Franco will work
on a consulting  basis out of the company's new  headquarters in Carney's Point,
New Jersey.

"Tom's  diverse work  experience  is an excellent  fit for our rapidly  evolving
company.  He is a highly  accomplished  financial  executive  with  expertise in
manufacturing,  importing and  distribution,  and with  demonstrated  success in
financing,  refinancing,  restructurings and mergers & acquisitions," said Gerry
Crocker, CEO, CannaPharmaRx.

In his most recent  position as Chief  Financial  Officer for ZPC Holdings,  Mr.
Della-Franco  led the  company's  Sarbanes  Oxley  (SOX)  compliance,  strategic
acquisitions,  LBOs,  private  equity  rounds  and was the key  contact  for due
diligence rounds prior to the company's sale to a Fortune 500 company.  Prior to
ZPC Holdings, Mr. Della-Franco worked as Senior Auditor for the auditing firm of
Peat, Marwick Mitchell & Company (now KPMG) in Philadelphia.

"For me,  the most  rewarding  position  is one  where I can have a  balance  of
strategic and hands-on  financial  management.  At  CannaPharmaRx,  I am looking
forward to helping to  identify  and capture  opportunities  to help the company
accelerate, expand and grow," said Mr. Della-Franco.

This week,  CannaPharmaRx  officially  announced  the  opening of its New Jersey
headquarters where its administrative offices, including finance, are now based.
Financial  information  can be found in the  company's  form 10-Q filing for the
fiscal third quarter ending September 30 which was filed with the Securities and
Exchange Commission on November 19.

About CannaPharmaRx:  Headquartered in Carney's Point, New Jersey, CannaPharmaRx
is a pharmaceutical  company whose mission is to advance cannabinoid  discovery,
science, research & development, and to bring novel prescription, veterinary and
personal care  cannabinoid-based  products to market in the U.S. and  worldwide.
For more information, visit www.cannapharmarx.com.

Forward  Looking  Statements:  Certain  statements  in this  press  release  are
forward-looking  within the meaning of the Private Securities  Litigation Reform
Act of 1995.  These  statements may be identified by the use of  forward-looking
words such as  "anticipate,"  "believe,"  "forecast,"  "estimated" and "intend,"
among others.  These  forward-looking  statements  are based on  CannaPharmaRx's
current  expectations  and actual results could differ  materially.  There are a
number of factors that could cause actual events to differ materially from those
indicated by such forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a going concern;
our need for  additional  financing;  uncertainties  of  patent  protection  and



litigation;  clinical  trials  involve a lengthy and  expensive  process with an
uncertain  outcome,  and  results  of  earlier  studies  and  trials  may not be
predictive of future trial results;  uncertainties of government or fourth party
payer  reimbursement;  limited sales and marketing  efforts and dependence  upon
fourth  parties;  and risks  related  to failure  to obtain  FDA  clearances  or
approvals and  noncompliance  with FDA regulations.  As with any  pharmaceutical
products under  development,  there are  significant  risks in the  development,
regulatory  approval  and  commercialization  of  new  products.  There  are  no
guarantees that future  clinical trials  discussed in this press release will be
completed or successful or that any product will receive regulatory approval for
any indication or prove to be commercially successful.

CannaPharmaRx  does  not  undertake  an  obligation  to  update  or  revise  any
forward-looking  statement.  Investors should read the risk factors set forth in
CannaPharmaRx's  private  placement  agreement and Form 10-Q as of September 30,
2014  (Unaudited)  and other  periodic  reports  filed with the  Securities  and
Exchange Commission.

SOURCE: CannaPharmaRx, Inc.
Contact: Kathleen Wolff, CannaPharmaRx, kwolff@cannapharmarx.com